Hajime Miyashita

Mr. Hajime Miyashita


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2025 in Micromachines
Verified
Journal Article
Open access
PDF file
HMHajime Miyashita
Hajime Miyashita
YIYuya Ito
Yuya Ito
KSKenta Shinha
Kenta Shinha
HNHiroko Nakamura
Hiroko Nakamura
Hiroshi KimuraHiroshi Kimura
Hiroshi Kimura
Traditional pre-clinical drug evaluation methods, including animal experiments and static cell cultures using human-derived cells, face critical limitations such as interspecies differences, ethical concerns, and poor physiological relevance. More recently, microphysiological systems (MPSs) that use microfluidic devices to mimic in vivo conditions have emerged as promising platforms. By enabling perfusion cell culture and incorporating human-derived cells, MPSs can evaluate drug efficacy and toxicity in a more human-relevant manner. However, standard MPS protocols rely on discrete medium changes, causing abrupt changes in drug concentrations that do not reflect the continuous pharmacokinetics seen in vivo. To overcome this limitation, we developed a Dialysis Membrane-integrated Microfluidic Device (DMiMD) which maintains continuous drug concentrations through selective medium change via a dialysis membrane. The membrane’s molecular weight cut-off (MWCO) enables the retention of high-molecular-weight drugs while facilitating the passage of essential low-molecular-weight nutrients such as glucose. We validated the membrane’s molecular selectivity and confirmed effective nutrient supply using cells. Additionally, anticancer drug efficacy was evaluated under continuously changing drug concentrations, demonstrating that the DMiMD successfully mimics in vivo drug exposure dynamics. These results indicate that the DMiMD offers a robust in vitro platform for accurate assessment of drug efficacy and toxicity, bridging the gap between conventional static assays and the physiological complexities of the human body.

14 July 2026 in Micromachines
Verified
Journal Article
Open access
PDF file
HMHajime Miyashita
Hajime Miyashita
KSKenta Shinha
Kenta Shinha
HNHiroko Nakamura
Hiroko Nakamura
MKMoeno Kadoguchi
Moeno Kadoguchi
HAHiroshi Arakawa
Hiroshi Arakawa
Hiroshi KimuraHiroshi Kimura
Hiroshi Kimura
Conventional in vitro assays and many microphysiological systems struggle to generate time-dependent drug exposure profiles because medium replacement simultaneously removes or re-adds drugs in the culture compartment. Here, we developed an Open-access Dialysis Membrane-integrated Microfluidic Device (O-DMiMD) that uses molecular weight-dependent transport across a dialysis membrane to decouple nutrient supply from drug exposure control. The device comprises a cell culture compartment (CCC) and a donor compartment (DC) separated by a dialysis membrane. Transport functions were evaluated using Lucifer Yellow, FITC-dextran, and glucose, followed by drug-response studies using SN-38 and T-DM1 under different medium change conditions. Lucifer Yellow and glucose permeated through the dialysis membrane, whereas FITC-dextran was retained. DC medium change supplied glucose to the CCC and maintained A549/HepG2 co-culture proliferation comparably to direct CCC medium replacement. For SN-38, partial transport to the DC and retention in the CCC generated time-dependent exposure profiles; in A549/HepaRG co-culture, medium change conditions altered A549 viability. For T-DM1, conditions with or without re-addition to the CCC produced different SK-BR-3 responses, suggesting exposure-dependent effects for high-molecular-weight drugs. The O-DMiMD provides an open-access in vitro platform for evaluating drug responses under exposure profiles governed by molecular weights, protein binding, medium changes, and metabolic cell contexts.